Atrium Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Could Turtle Pond discoveries extend the geological story behind Kenbridge nickel? (CSE: TN)

Vision Marine Technologies expands electric boating strategy through pontoon segment leadership and SPECTR 26 launch

Vision Marine (NASDAQ: VMAR) targets pontoon dominance with SPECTR 26 electric platform strategy

Why Canuc Resources Corporation is quietly expanding its Sudbury exploration corridor (TSXV: CDA)

#AtriumTherapeutics #RNATherapeutics #PrecisionCardiology #RareDisease #BiotechIPO #Cardiomyopathy

Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line

Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

February 28, 2026